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Abstract
 
The pre-T cell receptor (TCR) signals constitutively in the absence of putative ligands on thy-
mic stroma and signal transduction correlates with translocation of the pre-TCR into gly-
colipid-enriched microdomains (rafts) in the plasma membrane. Here, we show that the pre-
TCR is constitutively routed to lysosomes after reaching the cell surface. The cell-autonomous
down-regulation of the pre-TCR requires activation of the src-like kinase p56
 
lck
 
, actin poly-
merization, and dynamin. Constitutive signaling and degradation represents a feature of the
pre-TCR because the 
 
  
 
TCR expressed in the same cell line does not exhibit these features.
This is also evident by the observation that the protein adaptor/ubiquitin ligase c-Cbl is phos-
phorylated and selectively translocated into rafts in pre-TCR– but not 
 
  
 
TCR-expressing
cells. A role of c-Cbl–mediated ubiquitination in pre-TCR degradation is supported by the re-
duction of degradation through pharmacological inhibition of the proteasome and through a
dominant-negative c-Cbl ubiquitin ligase as well as by increased pre-TCR surface expression
on immature thymocytes in c-Cbl–deficient mice. The pre-TCR internalization contributes
significantly to the low surface level of the receptor on developing T cells, and may in fact be a
requirement for optimal pre-TCR function.
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Introduction
 
The pre-TCR is composed of the disulfide-linked TCR
 
 
 
/
pre-TCR
 
 
 
 (pT
 
 
 
)
 
*
 
 heterodimer in noncovalent association
with CD3 signal-transducing modules (1). The CD3
 
 
 
 and
CD3
 
 
 
 chains as well as the disulfide linked 
 
 
 
–
 
  
 
homodimer
were shown to play crucial roles in proximal signal trans-
duction by the pre-TCR (2–6), whereas the CD3
 
 
 
 chain
was shown to be associated with the pre-TCR (1) but dis-
pensable for its function (7, 8). Deletion of essential pre-
TCR–CD3 complex components induces a severe thymic
atrophy with a block at the G
 
0
 
/G
 
1
 
 phase of the cell cycle of
CD25
 
 
 
44
 
  
 
CD4
 
 
 
8
 
  
 
double negative (DN) 3 cells and arrest
of 
 
  
 
 T cells at DN stage of thymocyte development. Few
CD4
 
 
 
8
 
  
 
double positive (DP) cells were detected in pT
 
 
 
and 
 
 
 
 chain–deficient mice (4–6, 9, 10) and both pT
 
 
 
 and
 
 
 
 chains were required for the allelic exclusion of the
TCR
 
 
 
 locus (11, 12). These observations demonstrate that
the expression of the pre-TCR–CD3 complex by imma-
ture DN thymocyte regulates the development of the 
 
  
 
 T
cell lineage by ensuring efficient TCR
 
 
 
 selection with
proper transition to the DP stage. In addition to these roles
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Abbreviations used in this paper:
 
 DN, double negative; DP, double posi-
tive; ER, endoplasmic reticulum; EGFP, enhanced green fluorescent pro-
tein; FTOC, fetal thymic organ culture; HA, hemagglutinin; HRP,
horseradish peroxidase; LAMP, lysosomal-associated membrane protein;
PDI, protein disulfide isomerase; pT
 
 
 
, pre-T cell receptor 
 
 
 
; TRITC,
tetramethylrhodamine isothiocyanate. 
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Constitutive Down-regulation of the Pre-TCR
 
in T cell development, pre-TCR expression was recently
shown to be crucially involved in the development of leu-
kemia/lymphoma in Notch transgenic mice (13, 14).
Observations in transgenic mice expressing a TCR
 
 
 
chain with an attached endoplasmic reticulum (ER) re-
trieval signal clearly indicated that the exit of the pre-TCR
from the ER/
 
cis
 
-Golgi apparatus is required for the devel-
opment of the 
 
  
 
 T cell lineage (15). Mice expressing a
truncated pre-TCR devoid of the extracellular portion dis-
played efficient developmental progression, which sug-
gested that the pre-TCR functions independently of an ex-
ogenous ligand (16). The biochemical demonstration of
cell-autonomous translocation of the pre-TCR complex
into glycolipid-enriched membrane domains (rafts) and
cell-autonomous signaling supported this hypothesis, thus
defining differences in initiation of signaling between the
pre-TCR on the one hand and the 
 
  
 
TCR and 
 
  
 
TCR
on the other hand, the latter two requiring ligation to ob-
serve similar biochemical alterations (17).
Endocytosis and molecular sorting of receptors are
mainly regulated by dileucine- and tyrosine-based motifs
present in the cytoplasmic tails that act as coated pit local-
ization signals (18, 19). The dileucine-based motif identi-
fied in the CD3
 
 
 
 chain (20) can bind clathrin-coated vesi-
cle adaptor proteins in vitro and mediate endocytosis of the
TCR upon activation of protein kinase C (21). After pro-
tein kinase C–mediated internalization, the TCR is recy-
cled back to the cell surface upon CD3
 
 
 
 dephosphoryla-
tion (22). In contrast, antigenic stimulation and activation
of the p56
 
lck 
 
tyrosine kinase targets cell surface TCRs for
lysosomal degradation (23, 24). In resting cells, the TCR is
constitutively internalized and recycled back to the cell sur-
face. TCR ligation prevents recycling and initiates the deg-
radation of the TCR–CD3 complex (25). The recent dem-
onstration that ubiquitin carries an endocytosis signal (26,
27) and can target the degradation of monoubiquitinated
proteins leads to the hypothesis that CD3 and 
 
 
 
 chains that
are ubiquitinated after 
 
  
 
TCR engagement could play a
role in targeting activated TCR–CD3 complexes for lyso-
somal degradation. Indeed, most ubiquitinated plasma
membrane receptors are targeted for lysosomal degradation
(28, 29). The ubiquitination and internalization of several
growth factor receptors depend on the ubiquitin ligase ac-
tivity of the product of the protooncogene 
 
c-cbl 
 
(30–33),
which is phosphorylated after 
 
  
 
TCR stimulation (34).
The cell-autonomous signaling by the pre-TCR poses
the question of whether the fate of the receptor resembles
that of ligated TCRs and may, at least in part, be responsi-
ble for the low cell surface expression on developing thy-
mocyte. Here, we show that in contrast to the 
 
  
 
TCR
and 
 
  
 
TCR, the pre-TCR is constitutively routed to and
degraded in lysosomes. The rapid turnover is blocked by
sequestering monomeric actin, by the expression of a dom-
inant-negative dynamin, and by the inhibition of p56
 
lck 
 
ac-
tivation. Moreover, the diminution of pre-TCR degrada-
tion by proteasome inhibitors and the inhibition of c-Cbl
suggests that ubiquitination is involved in targeting the pre-
TCR to the degradative pathway.
 
Materials and Methods
 
Antibodies, Cell Lines, Retroviral Vectors, and Mice.
 
mAbs spe-
cific for the following antigens were used: protein disulfide
isomerase (PDI; provided by G. Gatti, Department of Biological
and Technological Research, University Hospital of San Raffaele
[Dibit-HSR], Milan, Italy), 
 
 
 
 actin (A-5441; Sigma-Aldrich), gi-
antin-CD107b (provided by H.P. Hauri, Biozentrum, Basel,
Switzerland; reference 35), CD3
 
 
 
 (145-2C11), TCR C
 
 
 
 (H57-
597), TCR V
 
 
 
8 (F23.1), CD4 (GK1.5), CD8 (53-6.7), CD25
(PC61), CD44 (IM7; BD PharMingen), TCR
 
 
 
 (3A10; reference
36), 
 
 
 
 chain (G3; reference 37), and phosphotyrosine (4G10; Up-
state Biotechnology). The following polyclonal immunoglobulins
were used: anti-CD3
 
 
 
 (sc-1127), anti–c-Cbl (sc-170), anti-p56
 
lck
 
(sc-433; Santa Cruz Biotechnology, Inc.), and rabbit anti–
 
 
 
 chain
(provided by L. Samelson, National Cancer Institute, Bethesda,
MD). For FACS
 
® 
 
analysis of pre-TCR expression, cells were
stained with biotinylated H57-597 mAb revealed by streptavi-
din–PBXL-3 (Martek). The SCID mice–derived thymocyte cell
lines SCIET.27, SCB.29 (38), SC
 
  
 
.28, SC
 
 
 
–enhanced green
fluorescent protein (EGFP; reference 17), the T cell hybridoma
B6.2.16 (38), and thymoma M14T (39) were used. In FACS
 
® 
 
ex-
periments, 10 
 
 
 
g/ml cycloheximide and 1 
 
 
 
M bafilomycin A1
were used. Cells were incubated with cycloheximide for 2 h, and
a 1-h incubation with bafilomycin preceded the cell culture with
the two drugs together. The EGFP-encoding bicistronic retrovi-
ral vector used in this study was derived by the matrix metallo-
proteinase vector (provided by J.-S. Lee, Harvard Medical
School, Boston, MA; reference 40) and constructed by E. Jaeckel
(Dana Farber Cancer Institute, Boston, MA). The plasmids en-
coding wild-type and K44A mutant dynamin (41) were obtained
from M. Fabbri (Dibit-HSR, Milan, Italy). Plasmids for wild-
type and mutant hemagglutinin (HA)-tagged c-Cbl were previ-
ously described (42). C-Cbl
 
 
 
/
 
  
 
C57BL/6 mice were used (43).
Embryos from timed C57BL/6 pregnant female mice were used
for fetal thymic organ culture (FTOC) and to obtain fetal thy-
mocytes for microscopy. FTOC in the presence of vehicle
(DMSO) or 10 
 
 
 
M PP2 (Calbiochem) was performed in IMDM,
sodium pyruvate, 2-mercaptoethanol, 
 
l
 
-glutamine, 20 mM
Hepes, Nutridoma SP (Boehringer-Mannheim), 0.4% lipid-free
BSA, and 8.1 
 
 
 
g/ml monothioglycerol.
 
Fluorescence Microscopy.
 
After adhesion on poly-
 
l
 
-lysine–
coated coverslip, SC
 
 
 
-EGFP cells were fixed in 3% paraformal-
dehyde and permeabilized in PBS, 0.15% Triton X-100 for 5
min. In some experiments, cells were pretreated for 6 h with 0.5
 
 
 
M bafilomycin A1 (Calbiochem) or with the vehicle of the
drug (DMSO) as a control. After permeabilization, slides were
incubated with the indicated antibodies followed by tetramethyl-
rhodamine isothiocyanate (TRITC)–labeled secondary antibody.
For staining with LysoTracker, cells were incubated in IMDM
complete medium, 100 nM LysoTracker for 2 h at 37
 
 
 
C. After
fixation and permeabilization, embryonic thymocytes were incu-
bated with goat polyclonal anti–TCR
 
 
 
 immunoglobulins fol-
lowed by a TRITC-labeled secondary antibody and then with
antilysosomal-associated membrane protein (LAMP)-2 mAb fol-
lowed by FITC-conjugated secondary antibody. The cells were
visualized on an integrated DeltaVision system (Applied Preci-
sion) including an IX70 inverted microscope with a 60
 
  
 
objec-
tive (Olympus). Images were captured with a cooled, charge-
coupled device camera (Princeton Instruments). 40–50 
 
z
 
-series
optical sections were captured at 0.2-
 
 
 
m intervals, and out of fo-
cus light was removed by iterative deconvolution on an Octane 2
workstation (Silicon Graphics). Projections were generated with
SoftwoRx software (Applied Precision). 
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Surface Labeling, Immunoprecipitation, and Electrophoresis.
 
Cell
surface biotinylation was performed as previously described (44).
In brief, cells were washed in PBS and incubated in 1 ml PBS, 5
mM NHS-LC-biotin (Pierce Chemical Co.) for 1 h at 4
 
 
 
C. After
washing in PBS, 20 mM glycine, the cells were lysed in 1% Brij
96 (Fluka) or 0.5% Triton X-100 (Bio-Rad Laboratories) and 60
mM N-octyl 
 
 
 
-glucopyranoside (Sigma-Aldrich) lysis buffer. In
proteasome inhibition experiments, cells were incubated with
200 nM epoxomicin (Boston Biochem) or vehicle (DMSO) as a
control. Immunoprecipitations of pre-TCR–associated CD3
 
 
 
chains were performed by dissociation of 1% Brij 96 TCR
 
 
 
-spe-
cific immunocomplexes and reprecipitations with CD3
 
 
 
-specific
antibodies as previously described (45). Immunodepletion of pre-
TCR–CD3 was achieved by three sequential immunoprecipita-
tions of 1% Brij 96 cell lysates using F23.1 mAb at 20 
 
 
 
g/ml
followed by protein A–Sepharose. For two-dimensional nonre-
ducing versus reducing SDS-PAGE, immunoprecipitates were run
in SDS sample buffer under nonreducing conditions in a discontinu-
ous Laemmli SDS–polyacrylamide (5–15% gradient) gel. The first
dimension strips were then equilibrated in reduced SDS sample
buffer for 30 min at room temperature and then run into a second
5–15% gradient SDS-polyacrylamide gel. The gels were blotted
onto nitrocellulose membrane (Amersham Pharmacia Biotech)
probed with horseradish peroxidase (HRP)–conjugated avidin
(Amersham Pharmacia Biotech), and then stripped and reprobed
with anti-CD3
 
 
 
 antibodies revealed by HRP-conjugated second-
ary antibodies for normalization.
 
Cell Fractionation and Sucrose Gradients.
 
After two washes in
ice-cold PBS, cells were resuspended in hypotonic buffer (20
mM Tris-HCl, pH 7.5, 1 mM EGTA, 1 mM MgCl
 
2
 
, 0.5 mM
DTT, and protease inhibitors) and incubated for 10 min on ice.
Cells were then disrupted by homogenization on ice with a
dounce homogenizer. Salt concentration was adjusted to 150
mM NaCl, and intact cells, nuclei, and cytoskeleton were pel-
leted by centrifugation at 5,000 rpm for 5 min in microcentrifuge
at 4
 
 
 
C. The low speed supernatant was centrifuged at 100,000 
 
g
 
for 60 min. The resulting pellet was considered the membrane
fraction and the supernatant was considered the soluble proteins
fraction. The pellet was lysed in Triton X-100/N-octyl 
 
 
 
-glu-
copyranoside and equal amounts of proteins of the various frac-
tions were loaded on gel. For sucrose gradient fractionations, cells
were lysed in Triton X-100 as previously described (46) and
equal amounts of solubilized proteins for the different samples
were mixed with 1 ml 80% sucrose and overlaid with two phases
of 2 ml 30% sucrose and 1 ml 5% sucrose, respectively. Samples
were centrifuged at 200,000 
 
g
 
 at 4
 
 
 
C for 14–16 h. Rafts fractions
(from 3 to 5) as well as loading zone fractions (from 9 to 12) were
pooled, resolved by SDS-PAGE in 8–15% gradient gels, trans-
ferred to nitrocellulose membranes, and blotted with anti–c-Cbl
and anti-Lck immunoglobulins.
 
Online Supplemental Material.
 
We provide the following as
supplemental material: (a) images of multiple SC
 
 
 
-EGFP cells
stained with PDI, giantin antibodies, or incubated with
LysoTracker showing the predominant localization of the pre-
TCR in lysosomes; (b) an image showing the colocalization of
TCR
 
  
 
and CD3 in multiple SC
 
 
 
-EGFP cells; (c) immunopre-
cipitation with TCR
 
 
 
 mAb of surface-labeled SCB.29 cells
showing the reduction of pre-TCR turnover in cells treated with
lactacystin; and (d) immunoblot analysis of SCB.29 cells with an-
tiubiquitin rabbit serum showing the diminution of free ubiquitin
upon proteasome inhibition with epoxomicin. Online supple-
mental figures are available at http://www.jem.org/cgi/content/
full/jem.20020047/DC1.
 
Results
 
Constitutive Targeting of the Pre-TCR to Lysosomes.
 
Trans-
fection of the SCID thymocyte-derived cell line SCIET.27
with a rearranged TCR
 
 
 
 gene leads to expression of
the pre-TCR in the plasma membrane (1). Microscopic
analysis of SCIET.27 cells transfected with TCR
 
 
 
-EGFP
(SC -EGFP) revealed the accumulation of the green fluo-
rescence in a vesicular intracellular compartment. The
identity of such a compartment was investigated by staining
with anti-PDI antibodies as a marker of ER, anti-giantin
antibodies to label the Golgi apparatus, and LysoTracker, a
red fluorescent dye that specifically accumulates in lyso-
somes. Fig. 1 shows the projections of multiple optical sec-
tions of selected cells in which the green fluorescence is ex-
clusively colocalized with the lysosomal probe. Almost 60%
of TCR -EGFP colocalized with the lysosomal marker on
different 0.2- m sections (Fig. 1, histogram and legend).
Incubation of cells with cycloheximide blocking the de
novo protein synthesis resulted in the diminution of green
fluorescence in TCR -EGFP–expressing cells, but not in
cells transfected with EGFP alone. However, the addition
of bafilomycin A1, which blocks the acidification of endo-
somes, counteracted the effect of cycloheximide, suggest-
ing that the diminution of fluorescence detected by cyclo-
heximide treatment was the result of the selective lysosomal
degradation of the TCR -EGFP fusion protein (Fig. 2 A).
To rule out an artificial TCR -EGFP fusion protein–
dependent routing of the pre-TCR to lysosomes, we ana-
lyzed pre-TCR–expressing thymocytes ex vivo. Micro-
scopic analysis of day-15 embryonic thymocytes after
permeabilization and intracellular staining with TCR  and
LAMP-2 antibodies revealed the colocalization of the two
antibodies in TCR -expressing cells (Fig. 2 B), which in-
dicates that the trafficking of the pre-TCR to lysosomes
occurred in vivo as well as in TCR -EGFP–transfected
cell lines (SC -EGFP). Intracellular staining of TCR -
EGFP–transfected cells with CD3  antibodies detected
with TRITC-labeled anti-Ig revealed the colocalization of
the two fluorochromes (Fig. 2 C), which suggests that pre-
TCR–associated CD3  chains were concomitantly tar-
geted to lysosomes. This conclusion was supported by
immunoblot analysis of CD3  molecules after bafilomy-
cin A1 treatment of the pre-TCR–expressing cell line
SCB.29, which is derived from SCIET.27 by transfection
with TCR  (1). 6 h after treatment with the drug a two-
fold increase in CD3  protein was detected. When the
same analysis was performed with the parental untrans-
fected SCIET.27 cell line or the   TCR transfectants
(SC  .28), bafilomycin A1 treatment had no effect on
CD3  levels, suggesting that the increase of CD3  levels in
SCB.29 cells was dependent on the association of CD3
with the pre-TCR (Fig. 2 D).
Limited Stability of the Pre-TCR in the Plasma Mem-
brane. The apparent difference in signal initiation by the
pre-TCR on one hand and the   TCR or   TCR on
the other (16, 17) is consistent with the constitutive rout-
ing of the pre-TCR to lysosomes and the spontaneous1588 Constitutive Down-regulation of the Pre-TCR
degradation of the pre-TCR resulting in the attenuation of
signaling. Such a sequence of events should be reflected in
differences of stability in the plasma membrane of the pre-
TCR versus   TCR or   TCR. This hypothesis was
tested by cell surface labeling with biotin and immunopre-
cipitation with either anti-TCR  or anti-TCR  mAbs of
cell lysates after a 2-h chase in culture. The pre-TCR and
  TCR turnover could be analyzed in the same cellular
Figure 2. Localization of the pre-
TCR in lysosomes in embryonic thy-
mocytes and targeting of CD3 to lyso-
somes by the pre-TCR. (A) FACS®
profile for green fluorescence of SC -
EGFP and SC-EGFP cells upon treat-
ment for 2 h with DMSO (control),
cycloheximide and DMSO (CXM),
and cycloheximide and bafilomycin A1
(CXM    Bafilomycin). (B, a) Phase-
contrast image of E15 thymocyte, (b)
staining with TCR  mAb in red, (c)
LAMP 2 mAb in green, and (d) merged
images. 10–20% cells per thymocyte
preparation were positive and displayed
comparable patterns. 50 z-series optical
sections were captured at 0.2- m inter-
vals. Bar, 10  m. (C) SC -EGFP cells
were treated with bafilomycin A1 for
6 h, permeabilized, and stained with
CD3  mAb followed by anti–hamster Ig
immunoglobulins coupled to TRITC.
A single section of one cell is displayed.
Images of multiple cells showing com-
parable patterns are provided as supple-
mental material (see Figure S2, available
at http://www.jem.org/cgi/content/
full/jem.20020047/DC1. (a) Phase-
contrast image, (b) TCR -EGFP, (c)
CD3 , and (d) merged images. Bar, 10
 m. (D) Immunoblot analysis of the in-
dicated cell lines with CD3  and   actin
antibodies after a 6-h treatment with
DMSO or bafilomycin A1. Relative
densitometric analysis is displayed.
Figure 1. Localization of the pre-TCR in lysosomes. SC -EGFP cells were permeabilized and stained with the indicated antibodies or incubated with
LysoTracker. (a) Phase-contrast image, (b) TCR -EGFP, (c) staining with the indicated reagent, and (d) merged images are shown. Images of multiple
cells showing comparable patterns are provided as supplemental material (see Figure S1, A–C, available at http://www.jem.org/cgi/content/full/
jem.20020047/DC1). 40–50 z-series optical sections were captured at 0.2- m intervals and processed by a DeltaVision system (Materials and Methods).
Bars, 10  m. The histogram shows the percentage of TCR -EGFP colocalized with the indicated marker on single 0.2- m sections. The obtained val-
ues were 1.72   3.1% (n   41) for PDI, 13.1   8.8% (n   61) for giantin, and 59.4   6.2% (n   94) for LysoTracker.1589 Panigada et al.
environment, i.e., in the SCB.29 and SC  .28 cell lines.
Because the expression of both the pre-TCR and   TCR
in SCIET.27 cells transfected with rearranged TCR  and
TCR  genes could induce   TCR activation in trans,
  TCR turnover was analyzed in the thymoma M14T
(39) and T cell hybridoma B6.2.16 (38). Two-dimensional
nonreduced versus reduced SDS-PAGE revealed that
88   6% (n   3) of the biotinylated pre-TCR detected
immediately after labeling was lost after a 2-h chase and re-
placed by unlabeled, de novo–synthesized pre-TCRs as
detected by coprecipitation of the same amount of CD3 
chains as revealed by immunoblot (Fig. 3 A). In contrast,
the same analysis performed on both   TCR- and
  TCR-expressing cell lines revealed no significant differ-
ences in the recoveries of labeled TCRs after a 2-h chase
(Fig. 3, B–E). These results show that the pre-TCR has a
turnover that is accelerated when compared with that of
the   TCR and   TCR.
Pre-TCR Degradation Requires Dynamin and Actin Poly-
merization. Dynamin is essential in many intracellular
trafficking events (47). The GTPase activity of dynamin
was shown to be involved in clathrin-mediated endocyto-
sis (41, 48) and caveolae internalization (49, 50). Recently,
clathrin-independent endocytosis of the IL-2 receptor as-
sociated with rafts was also shown to depend on dynamin
(51). We tested the involvement of dynamin in pre-TCR
endocytosis by the transduction of SCB.29 cells with bicis-
tronic retroviral vectors encoding EGFP and HA-tagged
wild-type dynamin or dominant-negative K44A mutant
(41). EGFP-positive cells were sorted and the expression
of dynamin was checked in Western blots with HA anti-
bodies. Immunoprecipitation from transduced SCB.29
cells that were kept for 2 h in culture after biotinylation
revealed the prolonged stability of pre-TCR chains in cells
expressing the K44A mutant dynamin compared with cells
transduced with wild-type dynamin (Fig. 4, A–C). This
suggests that the GTPase activity of dynamin is required
for pre-TCR endocytosis. The actin cytoskeleton was hy-
pothesized to be involved at various stages of the en-
docytic process from the spatial organization of the en-
docytic machinery to the vesicle movement into the
cytoplasm (52). Moreover, filamentous actin was shown to
accumulate in raft patches of lymphoid cells (53). To ana-
lyze the possible role of the actin cytoskeleton in pre-
TCR degradation, we treated SCB.29 cells with the drug
latrunculin B to sequester monomeric actin. Fig. 4 D
shows the immunoprecipitation of biotinylated CD3 
chains from SCB.29 cells after a 2-h chase in the presence
of decreasing concentrations of the drug. Densitometric
analysis of the immunoprecipitated bands demonstrated a
dose-dependent inhibition of CD3  chain degradation,
which suggests a role of actin cytoskeleton in the turnover
of the pre-TCR.
Tyrosine Kinase Activity of p56lck Influences Pre-TCR Ex-
pression in the Plasma Membrane. To test whether proximal
pre-TCR signaling influenced the level of pre-TCR ex-
pression in the plasma membrane, we treated SCB.29 cells
and embryonic day 15 FTOCs with the tyrosine kinase in-
hibitor PP2, which strongly and selectively inhibits p56lck
and p59fyn (54). Immunoprecipitation of biotinylated CD3 
chains from SCB.29 cells treated with 10  M PP2 during
the 2-h chase in culture revealed the increased stability of
CD3  (Fig. 5 A). FACS® analysis of PP2-treated SCB.29
cells showed that pre-TCR expression was increased
Figure 3. Limited stability of
the pre-TCR in the plasma
membrane. (A–D) Immunopre-
cipitation with the indicated an-
tibody of the cell line defined at
the bottom of each quadrant.
Cells were labeled at the surface
with biotin, lysed in 1% Brij 96,
and immunoprecipitates were
resolved by two-dimensional
nonreduced versus reduced
SDS-PAGE. Western blots with
avidin-HRP and CD3  antibod-
ies on stripped membranes of
immunoprecipitations performed
immediately after labeling (0)
and a 2-h chase in culture (2) are
shown. IP, immunoprecipita-
tion; WB, Western blots. (E)
Densitometric analysis of the dis-
played experiment (the mean of
the values obtained with the two
cell lines is plotted for   TCR).1590 Constitutive Down-regulation of the Pre-TCR
whereas CD8, which is also targeted to rafts (55), was not
affected by this treatment (unpublished data). On day 15,
FTOC PP2 treatment impaired the down-regulation of
CD25, which is characteristic of pre-TCR–driven differ-
entiation and resulted in higher levels of pre-TCR expres-
sion. No difference was observed with regard to   TCR
expression (Fig. 5 B). These results suggest that p56lck and
possibly p59fyn activation results in an increased turnover of
the pre-TCR in the plasma membrane.
Reduced Pre-TCR Turnover by Proteasome Inhibition. Li-
gation of the   TCR was shown to induce ubiquitina-
tion as well as targeting to lysosomes of the associated
CD3/  chains (56, 57, 23). On the other hand, inhibition
of the proteasome was reported to result in the stabiliza-
tion of the ligated   TCR at the cell surface (25). Be-
cause the pre-TCR seems to promote, in a ligand-inde-
pendent fashion, the same proximal signaling events that
occur upon ligation of the   TCR, we tested whether
epoxomicin, a cell permeable as well as a selective and ir-
reversible inhibitor of the proteasome (58), had any effect
on the stability of the surface-labeled pre-TCR. Incuba-
tion of SCB.29 cells with epoxomicin resulted in a 75%
inhibition of degradation of biotinylated pre-TCR pro-
teins as detected in a 2-h chase after biotinylation (Fig. 6
A). The same effect was observed upon treatment with
clastolactacystin   lactone, another inhibitor of the pro-
teasome (see Figure S3  available at http://www.jem.
org/cgi/content/full/jem.20020047/DC1). These results
show that proteasome activity is involved in the ligand-
independent degradation of the pre-TCR. Immunopre-
cipitation with TCR -specific antibodies followed by the
dissociation of the immunocomplexes and reprecipitation
with CD3 -specific antibodies showed that surface bio-
tinylated CD3  chains that were associated with the pre-
TCR were comparably degraded during the chase period
and that degradation was likewise sensitive to epoxomicin
(Fig. 6 B). In prothymocytes,   chains are associated with
the pre-TCR and critically contribute to pre-TCR sig-
naling (59). However,   chains can also be expressed inde-
pendently of CD3  chains in immature thymocytes and
are only partially recruited during signaling by the pre-
TCR (60). Therefore, we tested the stability of these pre-
TCR independent   chains in the plasma membrane of
SCB.29 cells by depleting SCB.29 cell lysates through
TCR -specific immunoprecipitation and analyzing the
remaining biotinylated   chains. The result revealed no
Figure 4. Inhibition of pre-TCR degradation by domi-
nant-negative dynamin and treatment with latrunculin B. (A
and B) Immunoprecipitation with TCR  mAb of Brij 96 ly-
sates from biotin-labeled SCB.29 cells expressing either wild-
type or dominant-negative K44A dynamin and two-dimen-
sional nonreduced versus reduced SDS-PAGE analysis of the
immunoprecipitates. Western blots with avidin-HRP and
with CD3  antibodies on stripped membranes of immuno-
precipitations performed immediately after labeling (0) and a
2-h chase in culture (2) are shown. IP, immunoprecipitation;
WB, Western blots. (C) Densitometric analysis with mean
percents   SD (n   4) of the recovered biotinylated receptor
at the two time points with transduced SCB.29 cells. (D)
Immunoprecipitation of CD3  chains with 145-2C11 mAb
from Triton X-100/octylglucoside lysates of biotin-labeled
SCB.29 cells that were treated during the 2-h chase time after
labeling with the indicated doses of latrunculin B. Samples
were resolved in a 15% gel and immunoblotted with avidin-
HRP and CD3  antibodies after membrane stripping. The
histogram plot of the normalized percentages of biotinylated
CD3  chains recovered in the displayed experiment is shown.
The experiment is representative of three independent assays.1591 Panigada et al.
significant differences in the amount of biotinylated  
chains recovered after the 2-h chase (Fig. 6 C), which im-
plies that pre-TCR–independent   chains are relatively
stable in the plasma membrane of SCB.29 cells and that a
significant fraction of   chains on the cell surface are not
internalized with the pre-TCR. These results suggest that
pre-TCR–associated signal transducing molecules are se-
lectively degraded.
Figure 5. Reduced turnover and
enhanced expression of the pre-
TCR upon the inhibition of p56lck
tyrosine kinase activity. (A) Immu-
noprecipitation of CD3  chains with
145-2C11 mAb from Brij 96 lysates
of biotin-labeled SCB.29 cells that
were treated during the 2-h chase
time after labeling with DMSO ( )
or 10  M PP2 ( ). Samples were
resolved in a 15% gel and immuno-
blotted with avidin-HRP and CD3 
antibodies after membrane stripping.
The histogram plot of the normal-
ized percentages of biotinylated
CD3  chains recovered in the dis-
played experiment is shown. The
experiment is representative of four
independent assays. (B) FACS® anal-
ysis of E15 24-h FTOC in the pres-
ence of DMSO (control) or 10  M
PP2 ( ). The indicated cell subpopulations were electronically gated and analyzed for TCR  versus CD25 and TCR  expression. Relative representa-
tions of the selected cell fractions with respective median fluorescence intensities are displayed.
Figure 6. Reduction of the pre-TCR turnover by proteasome inhibition. (A) Immunoprecipitation with TCR  mAb of SCB.29 cells lysed in 1% Brij
96 immediately after surface labeling with biotin (0) or a 2-h chase in the presence of DMSO ( ) or epoxomicin ( ). Two-dimensional nonreduced
versus reduced gels were revealed in Western blots with avidin-HRP and after stripping with CD3  antibodies. (B) Immunoprecipitation with 145-2C11
mAb of pre-TCR–associated CD3 chains as described in Materials and Methods. Two-dimensional nonreduced versus reduced gels were revealed as pre-
viously described. (C) Immunoprecipitation with G3 mAb of pre-TCR–independent   chains. After Western blots with avidin-HRP, membranes were
stripped and revealed with anti–  chain rabbit serum. IP, immunoprecipitation; WB, Western Blots. (D) Densitometric analyses of the biotinylated pre-
TCR chains, pre-TCR–associated CD3  chains, and pre-TCR–independent   chains recovered at the indicated times and in the presence of the indi-
cated treatment (means of at least two experiments are plotted).1592 Constitutive Down-regulation of the Pre-TCR
Role of c-Cbl Ubiquitin Ligase Domain in the Regulation of
Pre-TCR Turnover. c-Cbl was shown to bind to the SH3
domains of p56lck and p59fyn (61), as well as to phosphory-
lated ZAP-70 by its unique tyrosine kinase-binding do-
main (62, 63). The pre-TCR–dependent recruitment and
phosphorylation of ZAP-70 in the plasma membrane of
SCB.29 cells (17) could contribute to the twofold increase
in tyrosine phosphorylation of c-Cbl in pre-TCR–
expressing SCB.29 versus   TCR-expressing SC  .28
cells (Fig. 7 A). The same level of c-Cbl phosphorylation
as found in SCB.29 cells was obtained in SC  .28 after the
cross-linking of the   TCR with anti-TCR  mAbs. Sub-
cellular fractionation experiments revealed the selective
enrichment of c-Cbl in the plasma membrane and the par-
tition to rafts in SCB.29 cells, although c-Cbl was mostly
confined to the Triton X-100 soluble fractions in
both receptor-negative SCIET.27 and   TCR-expressing
SC  .28 cells (Fig. 7 B). These results suggest that c-Cbl is
specifically recruited and activated into rafts during pre-
TCR signaling. The RING finger domain of c-Cbl func-
tions as an ubiquitin protein ligase (64) and tyrosine phos-
phorylation at a site flanking such RING finger enables
Figure 7. Translocation of c-Cbl to rafts in pre-TCR–expressing cells and regulation of pre-TCR expression by c-Cbl. (A) Analyses by immunoblot
with antiphosphotyrosine mAb and anti-Cbl serum of c-Cbl immunoprecipitated from Triton X-100/octylglucoside lysates of the indicated cell lines.
Relative densitometric analysis is displayed. (B) Immunoblot with Cbl serum of particulate (m) and soluble (c) fractions from lysates of the indicated cell
lines (top), and the same analysis on rafts and Triton X-100 soluble (Txs) fractions from sucrose gradients loaded with lysates from the indicated cell lines.
After c-Cbl immunoblot, membranes were stripped and probed with anti-p56lck immunoglobulins as a control of fractionations (bottom). Densitometric
analyses of c-Cbl detected in rafts fractions of the indicated cell lines. Mean values   SD of three independent experiments are plotted. (C) Immunopre-
cipitation of CD3  chains with 145-2C11 mAb from Triton X-100/octylglucoside lysates of biotin-labeled SCB.29 cells expressing either wild-type or
dominant-negative c-Cbl at the indicated times after labeling. Samples were resolved in a 15% gel and immunoblotted with avidin-HRP and CD3 
immunoglobulins after membrane stripping. The histogram plot of the normalized percents   SD of biotinylated CD3  chains recovered in two inde-
pendent experiments is shown. (D) FACS® analysis of pre-TCR and   TCR expression on the surface of purified CD4 8  thymocytes that were further
electronically gated with CD4, CD8, CD44, and CD25 antibodies with different fluorochromes. Pre-TCR and   TCR expression on
CD44 4 8 CD25  and CD44 4 8 CD25  thymocytes, respectively, from c-Cbl /  and c-Cbl /  C57BL/6 mice were detected by biotinylated
TCR  and TCR   mAbs revealed by streptavidin labeled with PBXL-3. In TCR  histogram gray line represents the background fluorescence of an
isotype-matched biotinylated negative mAb revealed by PBXL-3. Mean percents   SD of pre-TCR and   TCR-positive cells recovered from six and
three mice, respectively, are plotted.1593 Panigada et al.
growth factor–dependent ubiquitination and degradation
of tyrosine kinase receptors (65). To analyze the role of the
c-Cbl ubiquitin ligase domain in pre-TCR down-regula-
tion, we transduced SCB.29 cells with bicistronic retrovi-
ral vectors encoding EGFP and either wild-type c-Cbl or a
dominant-negative RING finger mutant of c-Cbl with
cysteines 396, 401, and 404 mutated to alanine, and histi-
dine 398 to asparagine (C3AHN; reference 42). Surface la-
beling with biotin of transduced SCB.29 cells and immu-
noprecipitations of CD3  chains at different times of chase
showed the sustained recovery of biotinylated CD3 
chains in cells transduced with the dominant-negative
C3AHN c-Cbl with respect to cells transduced with the
wild-type c-Cbl (Fig. 7 C). This result demonstrated that
an intact c-Cbl RING domain regulates the constitutive
degradation of the pre-TCR–CD3 complex. The role of
c-Cbl in the control of pre-TCR turnover was further
demonstrated by the increased pre-TCR expression on
the cell surface of CD44 4 8 CD25  thymocytes from
c-Cbl–deficient mice, whereas   TCR expression was
unaltered in CD44 4 8 CD25   thymocytes from the
same mice (Fig. 7 D).
Discussion
The pre-TCR plays a critical role in thymus develop-
ment and determines the major wave of thymocyte prolif-
eration during T cell development through signaling that
apparently does not depend on interaction with exogenous
ligands (16, 17). Cell-autonomous signaling by the pre-
TCR is likely conferred to immature thymocytes by the
expression in the plasma membrane of the pT  chain co-
valently linked to the rearranged TCR  chain because the
exit from the ER/cis-Golgi was shown to be required for
pre-TCR signaling in the mouse (15). The pre-TCR is ex-
pressed at barely detectable levels on the surface of imma-
ture thymocytes. In human thymocytes this low expression
was proposed to be dependent on a reduced transport to
the plasma membrane determined by an ER retention mo-
tif present in the cytoplasmic tail of the human pT  chain
(66). We could not detect an accumulation of the murine
pre-TCR in the ER although we could localize the intra-
cellular pre-TCR predominantly in the endosomal/lysoso-
mal compartment. The observed endocytosis and deg-
radation of the pre-TCR suggests that attenuation of the
cell-autonomous signaling could be an important feature of
pre-TCR signaling. In fact, the overexpression of pT  was
shown to inhibit normal thymocyte differentiation (67).
Recently, the IL-2 receptor was shown to be translo-
cated into rafts and internalized upon IL-2 binding by a
clathrin-independent endocytic pathway through deter-
gent-resistant structures (51). Moreover, the sorting of the
IL-2 receptor to late endocytic compartments was shown
to depend on ubiquitination (68). The pre-TCR is likely
internalized by the same mechanism. The disruption of de-
tergent-resistant plasma membrane domains by cholesterol
extraction abolished pre-TCR signaling (17) and degrada-
tion (unpublished data). Polymerized actin accumulates in
rafts patches (53) and the actin cytoskeleton was hypothe-
sized to be involved in different steps of the endocytic pro-
cess, like membrane invagination and fission as well as vesi-
cle movement in the cytoplasm (52). We tested whether
sequestration of monomeric actin by the drug latrunculin B
had any effect on pre-TCR endocytosis. We found that
exposure of the pre-TCR–expressing cell line SCB.29 to
latrunculin B resulted in a dose-dependent inhibition of
pre-TCR degradation (Fig. 4 D), thus implying the in-
volvement of the actin cytoskeleton in sorting the pre-
TCR to lysosomes.
The product of the protooncogene c-cbl was shown to be
involved in the down-regulation of a number of growth
factor receptors and is phosphorylated after   TCR stimu-
lation (69). We have previously shown that c-Cbl is consti-
tutively phosphorylated in pre-TCR–expressing cells and
activated in recombinase-deficient thymocytes upon anti-
CD3 treatment (60). It was proposed that the phosphoryla-
tion and recruitment of c-Cbl by both Src family kinases
and ZAP-70/Syk could negatively regulate the signaling of
activated immune receptors through ubiquitin-dependent
endocytosis or postendocytic sorting to lysosomes (70). Ac-
cordingly, activated T cells display ubiquitinated CD3 and
  chains (56, 57) at the same time they are targeted to lyso-
somes (23), and c-Cbl–deficient mice display elevated CD3
expression on the cell surface of thymocytes (43). In-
deed,  pre-TCR expression in the plasma membrane of
CD44 4 8 CD25  thymocytes from such mice was also
increased (Fig. 7 D). In SCB.29 cells p21 and p23, phos-
phorylated    chains were detected in association with
ZAP-70 after long exposure of immunoblots revealed with
antiphosphotyrosine mAbs, which represent an extremely
sensitive reagent (59 and unpublished data). The lack of de-
tection of   chains with antiubiquitin antibodies in SCB.29
cells could be related to high instability and poor associa-
tion of such chains with the pre-TCR and/or the preva-
lence of monoubiquitinated forms (56) that are poorly rec-
ognized by the antisera.
A role of ubiquitination in regulating pre-TCR expres-
sion was implicated because of the observed stabilization of
the pre-TCR after the inhibition of the proteasome. Inhib-
itors of both proteasome and lysosomes were shown to af-
fect degradation of mammalian receptors that are ubiquiti-
nated upon ligand stimulation. It was hypothesized that
proteasome and lysosomes could be involved in the degra-
dation of different parts of the molecules or that protea-
some degradation of a nonreceptor protein might be re-
quired for targeting transport to the lysosomes (29).
Recently, ubiquitin was shown to function as an internal-
ization signal (26, 27) and in analogy to endocytosis medi-
ated by clathrin-coated pits, which is limited by saturable
components (71), it was shown to be rate-limiting for in-
ternalization (26). The accumulation of polyubiquitinated
proteins during the treatment with proteasome inhibitors
might interfere with the efficiency of receptor ubiquitina-
tion through the reduction of the pool of free ubiquitin
(58, 72, 73). In this respect, we observed a 53   10% (n  1594 Constitutive Down-regulation of the Pre-TCR
4) reduction of free ubiquitin by immunoblot upon treat-
ment of SCB.29 cells with 1  M epoxomicin for 6 h (see
Figure S4 available at http://www.jem.org/cgi/content/
full/jem.20020047/DC1). The reduced turnover of the
pre-TCR by the expression of the RING finger dominant-
negative c-Cbl mutant suggests a critical role of ubiquitina-
tion by c-Cbl in signal attenuation not only by negatively
regulating the intracellular effectors of the signaling ma-
chinery (42, 68, 74–77), but by determining the down-reg-
ulation of the pre-TCR itself. Furthermore, it was recently
shown that c-Cbl associated to activated receptor tyrosine
kinases could regulate their internalization through the re-
cruitment of endophilins, which are involved in the induc-
tion of plasma membrane invagination in the early phases
of endocytosis (78–79). Because c-Cbl is selectively re-
cruited to the plasma membrane by the pre-TCR, it could
also promote the endocytosis of pre-TCR–containing rafts
by this function.
Constitutive signaling by the pre-TCR induces the in-
crease in cytosolic Ca2  and the activation of nuclear factor
 B and nuclear factor of activated T cells (80). It is of inter-
est to note that the function of the pre-TCR at the DN
stage of thymocyte development cannot be replaced effi-
ciently by the   TCR. The early expression of an
  TCR leads to an inhibition of    T cell development
and the generation of CD4 8  thymocytes that express an
  TCR on the cell surface but do not or only inefficiently
proceed along the    pathway (81–83). Thus, it is likely
that the cell-autonomous signaling and endocytosis of the
pre-TCR are both required for effective    T cell devel-
opment, whereas the mere expression of an   TCR or
  TCR diverts cells to a different lineage fate by different
signals. Pre-TCR signal extinction by endocytosis and deg-
radation may represent an important aspect of pre-TCR
function as transgenic pT  overexpression resulted in the
increased proliferation of DN3 cells and the apoptosis of
DP thymocytes inhibiting    thymocyte development in a
copy number–dependent fashion (67).
Regarding the latter observations, it was shown that a
tumor-inhibitory mAb used in breast cancer immunother-
apy can enhance the c-Cbl–mediated ubiquitination and
degradation of the oncoprotein ErbB-2 expressed at the
cell surface, suggesting that ubiquitination and degradation
of receptor tyrosine kinases could be exploited for thera-
peutic purposes (84). Notch1-induced T cell leukemia in
mice develops only in the presence of pre-TCR signaling,
which suggests that deregulated expression of the pre-TCR
in a particular genetic context can be tumorigenic (13, 14).
Moreover, pT  chain expression was detected in all tested
human acute T lymphoblastic leukemias (13). The c-Cbl–
regulated proteolytic pathway described in this study could
represent a potential therapeutic target in pre-TCR–
dependent leukemia/lymphoma.
We thank Anja Siermann (Dana Farber Cancer Institute, Boston,
MA) for technical assistance, Giuliana Gatti, Hans-Peter Hauri,
Jeng-Shin Lee, and Elmar Jaeckel for antibodies and vectors, Larry
Samelson for constant supply of rabbit anti–  chain antiserum,
Monica Fabbri for dynamin plasmids and helpful discussions, and
David Dunlap for the help and use of the Alembic facility (Dibit-
HSR, Milano, Italy). 
F. Grassi is a recipient of a Special Fellow Award of The Leuke-
mia and Lymphoma Society.
Submitted: 10 January 2002
Revised: 9 April 2002
Accepted: 29 April 2002
References
1. Groettrup, M., K. Ungewiss, O. Azogui, R. Palacios, M.J.
Owen, A.C. Hayday, and H. von Boehmer. 1993. A novel
disulfide-linked heterodimer on pre-T cells consists of the T
cell receptor   chain and a 33 kD glycoprotein. Cell. 75:283–
294.
2. Haks, M.C., P. Krimpenfort, J. Borst, and A.M. Kruisbeek.
1998. The CD3  chain is essential for development of both
the TCR   and TCR   lineages. EMBO J. 17:1871–1882.
3. Malissen, M., A. Gillet, L. Ardouin, G. Bouvier, J. Trucy, P.
Ferrier, E. Vivier, and B. Malissen. 1995. Altered T cell de-
velopment in mice with a targeted mutation of the CD3 
gene. EMBO J. 14:4641–4653.
4. Malissen, M., A. Gillet, B. Rocha, J. Trucy, E. Vivier, C.
Boyer, F. Kontgen, N. Brun, G. Mazza, E. Spanopoulou, et
al. 1993. T cell development in mice lacking the CD3 / 
gene. EMBO J. 12:4347–4355.
5. Liu, C.P., R. Ueda, J. She, J. Sancho, B. Wang, G. Weddell,
J. Loring, C. Kurahara, E.C. Dudley, A. Hayday, et al. 1993.
Abnormal T cell development in CD3  /  mutant mice and
identification of a novel T cell population in the intestine.
EMBO J. 12:4863–4875.
6. Ohno, H., T. Aoe, S. Taki, D. Kitamura, Y. Ishida, K. Ra-
jewsky, and T. Saito. 1993. Developmental and functional
impairment of T cells in mice lacking CD3  chains. EMBO J.
12:4357–4366.
7. Berger, M.A., V. Dave, M.R. Rhodes, G.C. Bosma, M.J.
Bosma, D.J. Kappes, and D.L. Wiest. 1997. Subunit compo-
sition of pre-T cell receptor complexes expressed by primary
thymocytes: CD3  is physically associated but not function-
ally required. J. Exp. Med. 186:1461–1467.
8. Dave, V.P., Z. Cao, C. Browne, B. Alarcon, G. Fernandez-
Miguel, J. Lafaille, A. de la Hera, S. Tonegawa, and D.J.
Kappes. 1997. CD3  deficiency arrests development of the
   but not the    T cell lineage. EMBO J. 16:1360–1370.
9. Fehling, H.J., A. Krotkova, C. Saint-Ruf, and H. von Boeh-
mer. 1995. Crucial role of the pre-T-cell receptor   gene in
development of    but not    T cells. Nature. 375:795–798.
10. Fischer, A., and B. Malissen. 1998. Natural and engineered
disorders of lymphocyte development. Science. 280:237–243.
11. Aifantis, I., J. Buer, H. von Boehmer, and O. Azogui. 1997.
Essential role of the pre-T cell receptor in allelic exclusion of
the T cell receptor   locus. Immunity. 7:601–607.
12. Ardouin, L., J. Ismaili, B. Malissen, and M. Malissen. 1998.
The CD3    and CD3 /  modules are each essential for al-
lelic exclusion at the T cell receptor   locus but are both dis-
pensable for the initiation of V to (D)J recombination at the
T cell receptor- , - , and -  loci. J. Exp. Med. 187:105–116.
13. Bellavia, D., A.F. Campese, S. Checquolo, A. Balestri, A.
Biondi, G. Cazzaniga, U. Lendahl, H.J. Fehling, A.C. Hay-
day, L. Frati, et al. 2002. Combined expression of pT  and
Notch3 in T cell leukemia identifies the requirement of1595 Panigada et al.
preTCR for leukemogenesis. Proc. Natl. Acad. Sci. USA. 99:
3788–3793.
14. Allman, D., F.G. Karnell, J.A. Punt, S. Bakkour, L. Xu, P.
Myung, G.A. Koretzky, J.C. Pui, J.C. Aster, and W.S. Pear.
2001. Separation of Notch1 promoted lineage commitment
and expansion/transformation in developing T cells. J. Exp.
Med. 194:99–106.
15. O’Shea, C.C., A.P. Thornell, I.R. Rosewell, B. Hayes, and
M.J. Owen. 1997. Exit of the pre-TCR from the ER/cis-
Golgi is necessary for signaling differentiation, proliferation,
and allelic exclusion in immature thymocytes. Immunity.
7:591–599.
16. Irving, B.A., F.W. Alt, and N. Killeen. 1998. Thymocyte de-
velopment in the absence of pre-T cell receptor extracellular
immunoglobulin domains. Science. 280:905–908.
17. Saint-Ruf, C., M. Panigada, O. Azogui, P. Debey, H. von
Boehmer, and F. Grassi. 2000. Different initiation of pre-
TCR and   TCR signalling. Nature. 406:524–527.
18. Mellman, I. 1996. Endocytosis and molecular sorting. Annu.
Rev. Cell Dev. Biol. 12:575–625.
19. Kirchhausen, T., J.S. Bonifacino, and H. Riezman. 1997.
Linking cargo to vesicle formation: receptor tail interactions
with coat proteins. Curr. Opin. Cell Biol. 9:488–495.
20. Letourneur, F., and R.D. Klausner. 1992. A novel di-leucine
motif and a tyrosine-based motif independently mediate lyso-
somal targeting and endocytosis of CD3 chains. Cell. 69:
1143–1157.
21. Dietrich, J., J. Kastrup, B.L. Nielsen, N. Odum, and C. Gei-
sler. 1997. Regulation and function of the CD3  DxxxLL
motif: a binding site for adaptor protein-1 and adaptor pro-
tein-2 in vitro. J. Cell Biol. 138:271–281.
22. Dietrich, J., T. Backstrom, J.P. Lauritsen, J. Kastrup, M.D.
Christensen, F. von Bulow, E. Palmer, and C. Geisler. 1998.
The phosphorylation state of CD3  influences T cell respon-
siveness and controls T cell receptor cycling. J. Biol. Chem.
273:24232–24238.
23. Valitutti, S., S. Muller, M. Salio, and A. Lanzavecchia. 1997.
Degradation of T cell receptor (TCR)–CD3-  complexes af-
ter antigenic stimulation. J. Exp. Med. 185:1859–1864.
24. D’Oro, U., M.S. Vacchio, A.M. Weissman, and J.D. Ash-
well. 1997. Activation of the Lck tyrosine kinase targets cell
surface T cell antigen receptors for lysosomal degradation.
Immunity. 7:619–628.
25. Liu, H., M. Rhodes, D.L. Wiest, and D.A. Vignali. 2000. On
the dynamics of TCR:CD3 complex cell surface expression
and downmodulation. Immunity. 13:665–675.
26. Shih, S.C., K.E. Sloper-Mould, and L. Hicke. 2000. Monou-
biquitin carries a novel internalization signal that is appended
to activated receptors. EMBO J. 19:187–198.
27. Nakatsu, F., M. Sakuma, Y. Matsuo, H. Arase, S. Yamasaki,
N. Nakamura, T. Saito, and H. Ohno. 2000. A di-leucine
signal in the ubiquitin moiety. Possible involvement in ubiq-
uitination-mediated endocytosis. J. Biol. Chem. 275:26213–
26219.
28. Bonifacino, J.S., and A.M. Weissman. 1998. Ubiquitin and
the control of protein fate in the secretory and endocytic
pathways. Annu. Rev. Cell Dev. Biol. 14:19–57.
29. Hicke, L. 1999. Gettin’ down with ubiquitin: turning off
cell-surface receptors, transporters and channels. Trends Cell
Biol. 9:107–112.
30. Langdon, W.Y., J.W. Hartley, S.P. Klinken, S.K. Ruscetti,
and H.C. Morse III. 1989. v-cbl, an oncogene from a dual-
recombinant murine retrovirus that induces early B-lineage
lymphomas. Proc. Natl. Acad. Sci. USA. 86:1168–1172.
31. Levkowitz, G., H. Waterman, E. Zamir, Z. Kam, S. Oved,
W.Y. Langdon, L. Beguinot, B. Geiger, and Y. Yarden.
1998. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitina-
tion of the epidermal growth factor receptor. Genes Dev. 12:
3663–3674.
32. Lee, P.S., Y. Wang, M.G. Dominguez, Y.G. Yeung, M.A.
Murphy, D.D. Bowtell, and E.R. Stanley. 1999. The Cbl
protooncoprotein stimulates CSF-1 receptor multiubiquitina-
tion and endocytosis, and attenuates macrophage prolifera-
tion. EMBO J. 18:3616–3628.
33. Miyake, S., M.L. Lupher, B. Druker, and H. Band. 1998.
The tyrosine kinase regulator Cbl enhances the ubiquitina-
tion and degradation of the platelet-derived growth factor re-
ceptor  . Proc. Natl. Acad. Sci. USA. 95:7927–7932.
34. Donovan, J.A., R.L. Wange, W.Y. Langdon, and L.E.
Samelson. 1994. The protein product of the c-cbl protoon-
cogene is the 120-kDa tyrosine-phosphorylated protein in
Jurkat cells activated via the T cell antigen receptor. J. Biol.
Chem. 269:22921–22924.
35. Linstedt, A.D., and H.P. Hauri. 1993. Giantin, a novel con-
served Golgi membrane protein containing a cytoplasmic do-
main of at least 350 kDa. Mol. Biol. Cell. 4:679–693.
36. Itohara, S., N. Nakanishi, O. Kanagawa, R. Kubo, and S.
Tonegawa. 1989. Monoclonal antibodies specific to native
murine T-cell receptor   : analysis of    T cells during thy-
mic ontogeny and in peripheral lymphoid organs. Proc. Natl.
Acad. Sci. USA. 86:5094–5098.
37. van Oers, N.S., S.J. Teh, B.A. Irving, J. Tiong, A. Weiss, and
H.S. Teh. 1994. Production and characterization of mono-
clonal antibodies specific for the murine T cell receptor  
chain. J. Immunol. Methods. 170:261–268.
38. Groettrup, M., A. Baron, G. Griffiths, R. Palacios, and H.
von Boehmer. 1992. T cell receptor (TCR)   chain ho-
modimers on the surface of immature but not mature  ,  ,  
chain deficient T cell lines. EMBO J. 11:2735–2745.
39. Primi, D., R.A. Clynes, E. Jouvin-Marche, J.P. Marolleau, E.
Barbier, P.A. Cazenave, and K.B. Marcu. 1988. Rearrange-
ment and expression of T cell receptor and immunoglobulin
loci in immortalized CD4 CD8  T cell lines. Eur. J. Immu-
nol. 18:1101–1109.
40. Rebel, V.I., M. Tanaka, J.S. Lee, S. Hartnett, M. Pulsipher,
D.G. Nathan, R.C. Mulligan, and C.A. Sieff. 1999. One-day
ex vivo culture allows effective gene transfer into human
nonobese diabetic/severe combined immune-deficient re-
populating cells using high-titer vesicular stomatitis virus G
protein pseudotyped retrovirus. Blood. 93:2217–2224.
41. Damke, H., T. Baba, D.E. Warnock, and S.L. Schmid. 1994.
Induction of mutant dynamin specifically blocks endocytic
coated vesicle formation. J. Cell Biol. 127:915–934.
42. Ota, S., K. Hazeki, N. Rao, M.L. Lupher, Jr., C.E. An-
doniou, B. Druker, and H. Band. 2000. The RING finger
domain of Cbl is essential for negative regulation of the Syk
tyrosine kinase. J. Biol. Chem. 275:414–422.
43. Naramura, M., H.K. Kole, R.J. Hu, and H. Gu. 1998. Al-
tered thymic positive selection and intracellular signals in
Cbl-deficient mice. Proc. Natl. Acad. Sci. USA. 95:15547–
15552.
44. Leca, G., S.E. Mansur, and A. Bensussan. 1995. Expression of
VCAM-1 (CD106) by a subset of TCR   -bearing lympho-
cyte clones. Involvement of a metalloprotease in the specific
hydrolytic release of the soluble isoform. J. Immunol. 154:
1069–1077.1596 Constitutive Down-regulation of the Pre-TCR
45. Wiest, D.L., W.H. Burgess, D. McKean, K.P. Kearse, and A.
Singer. 1995. The molecular chaperone calnexin is expressed
on the surface of immature thymocytes in association with
clonotype-independent CD3 complexes. EMBO J. 14:3425–
3433.
46. Montixi, C., C. Langlet, A.M. Bernard, J. Thimonier, C.
Dubois, M.A. Wurbel, J.P. Chauvin, M. Pierres, and H.T.
He. 1998. Engagement of T cell receptor triggers its recruit-
ment to low-density detergent-insoluble membrane domains.
EMBO J. 17:5334–5348.
47. Schmid, S.L., M.A. McNiven, and P. De Camilli. 1998. Dy-
namin and its partners: a progress report. Curr. Opin. Cell
Biol. 10:504–512.
48. Sweitzer, S.M., and J.E. Hinshaw. 1998. Dynamin undergoes
a GTP-dependent conformational change causing vesicula-
tion. Cell. 93:1021–1029.
49. Henley, J.R., E.W. Krueger, B.J. Oswald, and M.A. Mc-
Niven. 1998. Dynamin-mediated internalization of caveolae.
J. Cell Biol. 141:85–99.
50. Oh, P., D.P. McIntosh, and J.E. Schnitzer. 1998. Dynamin at
the neck of caveolae mediates their budding to form transport
vesicles by GTP-driven fission from the plasma membrane of
endothelium. J. Cell Biol. 141:101–114.
51. Lamaze, C., A. Dujeancourt, T. Baba, C.G. Lo, A. Ben-
merah, and A. Dautry-Varsat. 2001. Interleukin 2 receptors
and detergent-resistant membrane domains define a clathrin-
independent endocytic pathway. Mol. Cell. 7:661–671.
52. Qualmann, B., M.M. Kessels, and R.B. Kelly. 2000. Molecu-
lar links between endocytosis and the actin cytoskeleton. J.
Cell Biol. 150:F111–F116.
53. Harder, T., and K. Simons. 1999. Clusters of glycolipid and
glycosylphosphatidylinositol-anchored proteins in lymphoid
cells: accumulation of actin regulated by local tyrosine phos-
phorylation. Eur. J. Immunol. 29:556–562.
54. Hanke, J.H., J.P. Gardner, R.L. Dow, P.S. Changelian,
W.H. Brissette, E.J. Weringer, B.A. Pollok, and P.A. Con-
nelly. 1996. Discovery of a novel, potent, and Src family-selec-
tive tyrosine kinase inhibitor. Study of Lck- and FynT-depen-
dent T cell activation. J. Biol. Chem. 271:695–701.
55. Arcaro, A., C. Gregoire, N. Boucheron, S. Stotz, E. Palmer,
B. Malissen, and I.F. Luescher. 2000. Essential role of CD8
palmitoylation in CD8 coreceptor function. J. Immunol. 165:
2068–2076.
56. Cenciarelli, C., D. Hou, K.C. Hsu, B.L. Rellahan, D.L.
Wiest, H.T. Smith, V.A. Fried, and A.M. Weissman. 1992.
Activation-induced ubiquitination of the T cell antigen re-
ceptor. Science. 257:795–797.
57. Hou, D., C. Cenciarelli, J.P. Jensen, H.B. Nguygen, and
A.M. Weissman. 1994. Activation-dependent ubiquitination
of a T cell antigen receptor subunit on multiple intracellular
lysines. J. Biol. Chem. 269:14244–14247.
58. Meng, L., R. Mohan, B.H. Kwok, M. Elofsson, N. Sin, and
C.M. Crews. 1999. Epoxomicin, a potent and selective pro-
teasome inhibitor, exhibits in vivo antiinflammatory activity.
Proc. Natl. Acad. Sci. USA. 96:10403–10408.
59. van Oers, N.S., H. von Boehmer, and A. Weiss. 1995. The
pre-T cell receptor (TCR) complex is functionally coupled
to the TCR-  subunit. J. Exp. Med. 182:1585–1590.
60. Grassi, F., E. Barbier, S. Porcellini, H. von Boehmer, and
P.A. Cazenave. 1999. Surface expression and functional com-
petence of CD3-independent TCR  -chains in immature
thymocytes. J. Immunol. 162:2589–2596.
61. Fukazawa, T., K.A. Reedquist, T. Trub, S. Soltoff, G. Pan-
chamoorthy, B. Druker, L. Cantley, S.E. Shoelson, and H.
Band. 1995. The SH3 domain-binding T cell tyrosyl phos-
phoprotein p120. Demonstration of its identity with the
c-cbl protooncogene product and in vivo complexes with
Fyn, Grb2, and phosphatidylinositol 3-kinase. J. Biol. Chem.
270:19141–19150.
62. Lupher, M.L., K.A. Reedquist, S. Miyake, W.Y. Langdon,
and H. Band. 1996. A novel phosphotyrosine-binding do-
main in the N-terminal transforming region of Cbl interacts
directly and selectively with ZAP-70 in T cells. J. Biol. Chem.
271:24063–24068.
63. Meng, W., S. Sawasdikosol, S.J. Burakoff, and M.J. Eck.
1999. Structure of the amino-terminal domain of Cbl com-
plexed to its binding site on ZAP-70 kinase. Nature. 398:84–
90.
64. Joazeiro, C.A., S.S. Wing, H. Huang, J.D. Leverson, T.
Hunter, and Y.C. Liu. 1999. The tyrosine kinase negative
regulator c-Cbl as a RING-type, E2-dependent ubiquitin-
protein ligase. Science. 286:309–312.
65. Levkowitz, G., H. Waterman, S.A. Ettenberg, M. Katz, A.Y.
Tsygankov, I. Alroy, S. Lavi, K. Iwai, Y. Reiss, A. Ciecha-
nover, et al. 1999. Ubiquitin ligase activity and tyrosine
phosphorylation underlie suppression of growth factor signal-
ing by c-Cbl/Sli-1. Mol. Cell. 4:1029–1040.
66. Carrasco, Y.R., A.R. Ramiro, C. Trigueros, V.G. de Ye-
benes, M. Garcia-Peydro, and M.L. Toribio. 2001. An endo-
plasmic reticulum retention function for the cytoplasmic tail
of the human pre-T cell receptor (TCR)   chain: potential
role in the regulation of cell surface pre-TCR expression lev-
els. J. Exp. Med. 193:1045–1058.
67. Lacorazza, H.D., H.E. Porritt, and J. Nikolich-Zugich. 2001.
Dysregulated expression of pre-T  reveals the opposite ef-
fects of pre-TCR at successive stages of T cell development.
J. Immunol. 167:5689–5696.
68. Rocca, A., C. Lamaze, A. Subtil, and A. Dautry-Varsat.
2001. Involvement of the ubiquitin/proteasome system in
sorting of the interleukin 2 receptor   chain to late endocytic
compartments. Mol. Biol. Cell. 12:1293–1301.
69. Thien, C.B., and W.Y. Langdon. 2001. Cbl: many adapta-
tions to regulate protein tyrosine kinases. Nat. Rev. Mol. Cell
Biol. 2:294–307.
70. Lupher, M.L., N. Rao, M.J. Eck, and H. Band. 1999. The
Cbl protooncoprotein: a negative regulator of immune re-
ceptor signal transduction. Immunol. Today. 20:375–382.
71. Warren, R.A., F.A. Green, P.E. Stenberg, and C.A. Enns.
1998. Distinct saturable pathways for the endocytosis of dif-
ferent tyrosine motifs. J. Biol. Chem. 273:17056–17063.
72. Swaminathan, S., A.Y. Amerik, and M. Hochstrasser. 1999.
The Doa4 deubiquitinating enzyme is required for ubiquitin
homeostasis in yeast. Mol. Biol. Cell. 10:2583–2594.
73. Schubert, U., D.E. Ott, E.N. Chertova, R. Welker, U. Tess-
mer, M.F. Princiotta, J.R. Bennink, H.G. Krausslich, and
J.W. Yewdell. 2000. Proteasome inhibition interferes with
gag polyprotein processing, release, and maturation of HIV-1
and HIV-2. Proc. Natl. Acad. Sci. USA. 97:13057–13062.
74. Ota, Y., and L.E. Samelson. 1997. The product of the proto-
oncogene c-cbl: a negative regulator of the Syk tyrosine ki-
nase. Science. 276:418–420.
75. Lupher, M.L., Jr., N. Rao, N.L. Lill, C.E. Andoniou, S.
Miyake, E.A. Clark, B. Druker, and H. Band. 1998. Cbl-
mediated negative regulation of the Syk tyrosine kinase. A
critical role for Cbl phosphotyrosine-binding domain binding
to Syk phosphotyrosine 323. J. Biol. Chem. 273:35273–1597 Panigada et al.
35281.
76. Rao, N., M.L. Lupher, Jr., S. Ota, K.A. Reedquist, B.J.
Druker, and H. Band. 2000. The linker phosphorylation site
Tyr292 mediates the negative regulatory effect of Cbl on
ZAP-70 in T cells. J. Immunol. 164:4616–4626.
77. Andoniou, C.E., N.L. Lill, C.B. Thien, M.L. Lupher, Jr., S.
Ota, D.D. Bowtell, R.M. Scaife, W.Y. Langdon, and H.
Band. 2000. The Cbl proto-oncogene product negatively
regulates the Src-family tyrosine kinase Fyn by enhancing its
degradation. Mol. Cell. Biol. 20:851–867.
78. Petrelli, A., G.F. Gilestro, S. Lanzardo, P.M. Comoglio, N.
Migone, and S. Giordano. 2002. The endophilin-CIN85-
Cbl complex mediates ligand-dependent downregulation of
c-Met. Nature. 416:187–190.
79. Soubeyran, P., K. Kowanetz, I. Szymkiewicz, W.Y. Lang-
don, and I. Dikic. 2002. Cbl-CIN85-endophilin complex
mediates ligand-induced downregulation of EGF receptors.
Nature. 416:183–187.
80. Aifantis, I., F. Gounari, L. Scorrano, C. Borowski, and H.
von Boehmer. 2001. Constitutive pre-TCR signaling pro-
motes differentiation through Ca2  mobilization and activa-
tion of NF- B and NFAT. Nat. Immunol. 2:403–409.
81. Bruno, L., H.J. Fehling, and H. von Boehmer. 1996. The   
T cell receptor can replace the    receptor in the develop-
ment of    lineage cells. Immunity. 5:343–352.
82. Fritsch, M., A. Andersson, K. Petersson, and F. Ivars. 1998. A
TCR   chain transgene induces maturation of CD4 8     
T cells from    T cell precursors. Eur. J. Immunol. 28:828–
837.
83. Terrence, K., C.P. Pavlovich, E.O. Matechak, and B.J.
Fowlkes. 2000. Premature expression of T cell receptor
(TCR)   suppresses TCR   gene rearrangement but per-
mits development of    lineage T cells. J. Exp. Med. 192:
537–548.
84. Klapper, L.N., H. Waterman, M. Sela, and Y. Yarden. 2000.
Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by
recruiting c-Cbl and enhancing ubiquitination of HER-2.
Cancer Res. 60:3384–3388.